Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 7/20 | 1.00 |
| ▸ | CDK2 | P24941 | 4/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 3/20 | 1.00 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 1.00 |
| ▸ | SMG1 | Q96Q15 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | CDK4 | P11802 | 2/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 2/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 2/20 | 1.00 |
| ▸ | CCND1 | P24385 | 2/20 | 1.00 |
| ▸ | CDK7 | P50613 | 2/20 | 1.00 |
| ▸ | CCNH | P51946 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | XBP1 | P17861 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 1/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29397852 | 1.00 | CDK1 (1.00) | CDK1CDK2CDK5CDK5R1SMG1 | |
| SCHEMBL29385808 | 1.00 | CDK1 (1.00) | CDK1CDK2CDK5CDK5R1SMG1 | |
| SCHEMBL30782585 | 1.00 | CDK1 (1.00) | CDK1CDK2CDK5CDK5R1SMG1 | |
| SCHEMBL7813303 | 0.98 | CDK1 (0.96) | CDK1CDK2CDK5CDK5R1SMG1 | |
| SCHEMBL7804352 | 0.97 | CDK1 (0.94) | CDK1CDK2CDK5CDK5R1SMG1 | |
| SCHEMBL7817083 | 0.95 | CDK1 (0.91) | CDK1CDK2CDK5CDK5R1SMG1 | |
| SCHEMBL6094407 | 0.94 | CDK1 (0.88) | CDK1CDK2CDK5CDK5R1SMG1 | |
| SCHEMBL7813759 | 0.92 | CDK1 (0.85) | CDK1CDK2CDK5CDK5R1SMG1 | |
| SCHEMBL7813870 | 0.92 | CDK1 (0.85) | CDK1CDK2CDK5CDK5R1SMG1 | |
| SCHEMBL14040966 | 0.92 | CDK1 (0.85) | CDK1CDK2CDK5CDK5R1SMG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10866241-B2 | Method for the prognosis and treatment of cancer metastasis | INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ES) | 2020-12-15 | — | — | US | claimed |
| US-20080187575-A1 | Pyrimidine Derivatives | VICHEM CHEMIE KFT (HU) | 2008-08-07 | — | — | US | claimed |
| EP-0672041-B1 | PHARMACOLOGICALLY ACTIVE PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2001-11-14 | — | — | EP | claimed |
| WO-1997032589-A1 | COMBINATIONS FOR TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | claimed |
| WO-1997032604-A1 | ANTIPROLIFERATIVE COMBINATIONS, CONTAINING RAF-TARGETED OLIGONUCLEOTIDES AND CHEMOTHERAPEUTIC COMPOUNDS | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | claimed |
| EP-0672041-A1 | PHARMACOLOGICALLY ACTIVE PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1995-09-20 | — | — | EP | claimed |
| WO-1995009853-A1 | PHARMACOLOGICALLY ACTIVE PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | CIBA-GEIGY AG (CH) | 1995-04-13 | — | — | WO | claimed |
| CN-117379432-B | Application of compound or medicinal salt thereof in preparing medicament for treating and preventing diseases caused by porcine pseudorabies virus | 北京大学 | 2024-03-08 | — | — | CN | disclosed |
| CN-117618434-A | Application of compound CGP60474 in preparation of medicines for treating and preventing diseases caused by type I herpesvirus | 北京大学 | 2024-03-01 | — | — | CN | disclosed |
| CN-117379432-A | Application of compound or medicinal salt thereof in preparing medicament for treating and preventing diseases caused by porcine pseudorabies virus | 北京大学 | 2024-01-12 | — | — | CN | disclosed |
| US-20220218571-A1 | HYDROGEL DRUG DELIVERY COMPOSITION | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2022-07-14 | — | — | US | disclosed |
| US-20220133740-A1 | VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS | Frequency Therapeutics, Inc. (US) | 2022-05-05 | — | — | US | disclosed |
| US-10940188-B2 | Compounds and methods for treatment and prevention of Flavivirus infection | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| WO-2006021458-A2 | PYRIMIDINE DERIVATIVES | GPC BIOTECH AG (DE) | 2006-03-02 | — | — | WO | disclosed |
| EP-1292190-B1 | N-PHENYL-4-(4-PYRIDYL)-2-PYRIMIDINEAMINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2005-08-24 | — | — | EP | disclosed |
| US-20030236256-A1 | N-phenyl-4-(4-pyridyl)-2-pyrimidineamine derivatives | SYNGENTA CROP PROTECTION, INC. | 2003-12-25 | — | — | US | disclosed |
| US-20030201208-A1 | Dynamic superparamagnetic markers | KOCH, MARTIN (DK) | 2003-10-30 | — | — | US | disclosed |
| US-5744460-A | SYNERGISTIC OF MIXTURE OF PROTEIN KINASE C-TARGETED ANTISENSE OLIGONUCLEOTIDE AND A CHEMOTHERAPEUTIC AGENT, E.G.VINBLASTINE; SIDE EFFECT REDUCTION; ANTICARCINOGENIC- AND TUMOR AGENTS | NOVARTIS CORPORATION (US) | 1998-04-28 | — | — | US | disclosed |
| WO-1997032589-A1 | COMBINATIONS FOR TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | disclosed |
| WO-1997032604-A1 | ANTIPROLIFERATIVE COMBINATIONS, CONTAINING RAF-TARGETED OLIGONUCLEOTIDES AND CHEMOTHERAPEUTIC COMPOUNDS | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10940188-B2 | Compounds and methods for treatment and prevention of Flavivirus infection | CDK2, CDKN1A, PSENEN | CDK1 8/4885CDK2 1/4885CDK5 5/4885 |
| US-20030236256-A1 | N-phenyl-4-(4-pyridyl)-2-pyrimidineamine derivatives | HRH4, HRH3, HRH2 | CDK1 2196/4885CDK2 1085/4885CDK5 1081/4885 |
| US-20220218571-A1 | HYDROGEL DRUG DELIVERY COMPOSITION | PTH1R, PHPT1, PTMS | CDK1 2227/4885CDK2 3192/4885CDK5 693/4885 |
| US-20080187575-A1 | Pyrimidine Derivatives | TYMP, TDP1, PNP | CDK1 264/4885CDK2 363/4885CDK5 89/4885 |
| US-20220133740-A1 | VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS | WNT3A, WNT1, WNT3 | CDK1 3063/4885CDK2 3018/4885CDK5 1567/4885 |
| US-10866241-B2 | Method for the prognosis and treatment of cancer metastasis | MAFG, BRCA1, BCOR | CDK1 2928/4885CDK2 4303/4885CDK5 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.